Q-Line Biotech Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Q-Line Biotech Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹343
Per ShareLot Size
400 Shares
Minimum Investment
₹1,37,200
Issue Size
₹214.48 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35%
QIB Quota
49.99%
NII Quota
15.01%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Q-Line Biotech Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
92.24%
Promoter Holding (Post-Issue)
67.51%
Issue Type
Book Building - SME
ISIN
INE1G2W01011
About the Company
We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of our Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).
Industry Overview
The India In-Vitro Diagnostics (IVD) market has experienced dynamic shifts, primarily driven by the COVID-19 pandemic. The market surged from 1,237 million USD in CY19 to 2,142 million USD in CY21 due to increased testing demand, followed by a sharp decline in CY22 and CY23 due to a high base from COVID-19 testing, which was not sustainable for continued growth, along with reduced pandemic-related testing. However, with growing healthcare awareness, and rising prevalence of chronic diseases, the market began recovering in CY24 and is projected to grow at a CAGR of up to 12.0%, reaching 2,978 million USD by CY30. This growth is likely to be driven by development of testing facilities and the rising burden of lifestyle diseases. With a steady demand for preventive healthcare, the market is expected to continue growth momentum, solidifying its critical role in India's healthcare sector.
Company History
Our Company was originally incorporated as "POCT Services Private Limited" on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to "Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to "Q-Line Biotech Limited", and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528.
Growth Strategy
- Expanding presence in existing markets and entering new ones.
- Exploring Strategic Alliances in CMO/CDMO Services.
- Grow manufacturing and production capacities aligned with the "Make In India" initiative of GoI.
- Expanding our existing product portfolio.
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY23 to FY25.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offer of upto 62,53,200 equity shares of face value of Rs. 10/- each (the "Equity Shares") of Q-Line Biotech Limited ("the Company" or "QLBL" or "the Issuer") at an issue price of Rs. 343 per equity share (including share premium of Rs. 333 per equity share) for cash, aggregating up to Rs. 214.48 Crores ("Public Issue") out of which 3,13,200 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 343 per equity share for cash, aggregating Rs. 10.74 Crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. Issue of 59,40,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 343 per equity share for cash, aggregating upto Rs. 203.74 Crores is herein after referred to as the "Net Issue". The public issue and net issue will constitute 26.81% and 25.46% respectively of the post- issue paid-up equity share capital of the company. The company, in consultation with the book running lead managers, may consider a pre-ipo placement of up to 8,00,000 equity shares for cash consideration ("pre-ipo placement") prior to filing of the pre-ipo placement, if undertaken, will be at a price to be decided by the company, in consultation with the book running lead managers. If the pre-ipo placement is undertaken, the number of equity shares issued pursuant to the pre-ipo placement shall be reduced from the issue, subject to compliance with Rule 19(2)(b) of the securities contracts (Regulation) rules, 1957, as amended ("scrr"). Price Band: Rs. 343 per equity share of face value Rs. 10/- each. The floor price (Rs.343) is 34.3 times of the face value of the equity shares. Bids can be made for a minimum of 800 equity shares and in multiples of 400 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control.
- Diversified product portfolio with focus on IVD industry.
- Widespread distribution network with a presence across all four regions.
- Long standing relationships with customers.
- Track record of healthy financial performance.
- Any disruption, stoppage, slowdown or shutdown in the company manufacturing facilities or process or research and development activities could adversely affect its business, financial condition, cash flows and results of operations.
- Any delay, interruption or reduction in the supply of the company raw materials, trade goods from its suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of the company products and has an adverse effect on the company business, financial condition, cash flows and results of operations.
- The company business is dependent on the sale of its products through distributors which also include the company group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of its products and could negatively impact the company business, results of operations, financial conditions and cash flows.
- The company is dependent on certain key suppliers to procure a significant portion of the company Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in its operations, which could has an adverse effect on the company business, financial condition, results of operations and cash flows.
- The company is required to obtain, maintain or renew its statutory and regulatory approvals, licenses, and registrations to operates the company business.